Phase I/IIB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy and Dose Escalation of RAD001 in Patients With Esophageal Cancer

Trial Profile

Phase I/IIB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy and Dose Escalation of RAD001 in Patients With Esophageal Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Everolimus (Primary) ; Capecitabine; Carboplatin; Cetuximab; Oxaliplatin; Paclitaxel
  • Indications Adenocarcinoma; Oesophageal cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Mar 2018 Planned End Date changed from 1 May 2019 to 1 May 2020.
    • 10 Mar 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
    • 06 Jun 2017 Results (n=19) from phase IB portion of the study, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top